News and Events
Learn more about current happenings at Ergomed.
Guildford, UK – 9 March 2015: Ergomed plc, (LSE: ERGO) a profitable UK-based company, dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, will announce its Preliminary Results for the year ended 31st December, 2014 on Wednesday 25th March, 2015.
Dr Miroslav Reljanovic, Chief Executive Officer and Neil Clark, Chief Financial Officer, will host a presentation for analysts at 9am GMT at Stifel Nicolaus Europe Limited (previously Oriel Securities Ltd) offices, 150 Cheapside, London, EC2V 6ET.
For further information, please contact:
Mary Clark, Supriya Mathur and Hollie Vile
Tel: + 44 203 440 5654
Stifel Nicolaus Europe Limited
NOMAD/Broker to the Company
Jonathan Senior, Giles Balleny
Tel: +44 207 710 7600
Ergomed Plc is a profitable UK-based company, providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 40 countries.
Ergomed provides clinical development, trial management and pharmacovigilance services to over 60 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.
Ergomed has a wide therapeutic focus, with a particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.
As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed leverages its expertise and services in return for carried interest in the drugs under development. For further information, visit: http://www.ergomedplc.com